Proteome Sciences are pleased to announce the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will enable the Company to extend its proteomic services to the analysis of clinical trial samples.
Proteome Sciences are a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. They offer various Discovery Services to characterise proteins and their associated post translational modifications. By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, they can detect many thousands of proteins per sample. With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
ELISA kits cover 5% of the human proteome, so there are usually no available assay kits to these disease relevant protein biomarkers. The challenge has been how to convert these novel identified biomarkers into assays fit for use in a clinical trial.
Following identification above, Proteome Sciences can now a develop a targeted SRM Mass Spectrometry based assay which, after validation, can be used for fit-for-purpose biomarker assays in a GCLP certified clinical trial environment. This can be done for one to 50 proteins in a single multiplexed assay.
For further information:
Richard Dennis, Chief Commercial Officer Tel: +44 (0)20 7043 2116